IARF Conference Secure Registration
ICOCTD · Registering as Listener

International Conference on Oncology and Cancer Therapeutics Development

28–29 Sep 2026 Hiroshima, Japan Standard / Physical Participation
Listener Registration
$140
virtual · $200 in person
Registration Benefits:
Official invitation letterIssued automatically after registration
Certificate & digital materialsGet certificate, slides and resource materials
Supporting global researchConnect with researchers across 30+ countries

Select registration mode

Prices are shown before tax and bank charges — no surprises at checkout.

!
Standard Registration Closed
The deadline for Standard Participation has ended. Participants may continue with Virtual Registration to join the conference remotely.
All sessions Networking Certificate Invitation letter Conference kit

Your details

We only need what's required to register and email your confirmation. Everything else is optional.

Coupon code

Have a code? Apply it here — the discount updates the total immediately.

Apply
View full Refund, Cancellation & Terms policy
Conference Programme and Participation Policy

Depending on accepted submissions and scheduling needs, the Organiser may combine compatible research themes across disciplines within an interdisciplinary or multidisciplinary programme that supports knowledge sharing, networking, and professional cooperation.

Refund, Cancellation, Postponement, Travel and Transfer of Registration:
Refund Policy:

If the registrant is unable to attend and is not in a position to transfer his/her participation to another person or event, then the following refund arrangements apply: Keeping given advance payments towards Venue, Printing, Shipping, Hotels, and other overheads, we had to keep the Refund Policy as the following slabs:

1. Cancellations made before 60 days of the conference are eligible for a full refund, subject to a $100 cancellation charge.
2. Cancellations made within 60-30 days of the conference are eligible for a 50% payment refund.
3. Cancellations made within 30 days of the conference are not eligible for a refund.
4. Virtual Participation registrations are non-refundable.

(a) The above refund policies are applicable only if the registrant has not received the official invitation letter for participation in the event, If the client receives the conference invitation letter but cannot attend the conference, no refund will be provided.

(b) If the client cannot attend the conference for any personal reasons, the registration fee is not refundable. However, the fee will be considered as a credit to participate in any of our international conferences within one year from the date of registration.

(c) In the event of a visa denial, travel reasons, or natural calamities preventing attendance, the registration fee will not be refunded. However, the fee will be considered as a credit to participate in any of our international conferences within one year from the date of registration.

(d) Since this conference is hybrid, the organizer reserves the right to conduct it in any format, physical or virtual. Refunds will not be provided for format changes.

(e) For participants who register close to the conference date or after the standard registration deadline, The registration will be considered for virtual participation only, as the conference is in hybrid mode. However, you will be eligible to attend one more international conference based on your registration category.

Cancellation Policy:

If the organizer cancels this event for any reason, you will receive a credit for 100% of the registration fee paid. You may use this credit for another event which must occur within one year from the date of cancellation.

Postponement of Event:

If the organizer postpones an event for any reason and you are unable or unwilling to attend on rescheduled dates, you will receive a credit for 100% of the registration fee paid. You may use this credit for another event which must occur within one year from the date of postponement.

Travel and Accommodation Responsibilities:

a) The responsibility for making and managing travel arrangements, including flights, transportation, and accommodation, lies solely with the individual participant.

b) In the event of any changes to the conference format, cancellation, or venue adjustments, the organizers cannot assume responsibility for any costs incurred by participants for travel or accommodation.

Transfer of registration:

All fully paid registrations are transferable to other persons from the same organization if the registered person is unable to attend the event. Transfers must be made by the registered person in writing to [email protected]. Details must include the full name of the replacement person, their title, contact phone number, and email address. All other registration details will be assigned to the new person unless otherwise specified. Registration can be transferred from one conference to another conference of the same organizer if the registrant is unable to attend one of the conferences

However, Registration cannot be transferred if it is intimated within 14 days of the respective conference. The transferred registrations will not be eligible for Refund.

Visa Information:

The organizer will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should take responsibility for their visa and travel arrangements. Important note for failed visa applications: Visa issues cannot come under the consideration of the cancellation policy of the organizer, including the inability to obtain a visa.

N.B:

All cancellations or modifications of registration must be made in writing to [email protected]

Payments encrypted & processed securely. Refundable up to 14 days before the event.

What you'll hear about

Session tracks covered across the conference.

This track will explore the latest innovations in cancer treatment modalities, including chemotherapy, radiotherapy, and targeted therapies. Emphasis will be placed on the integration of novel agents and treatment regimens in clinical practice.
This session will focus on the role of precision medicine in tailoring cancer treatment to individual patient profiles. Discussions will include the use of genomic data and biomarkers to enhance therapeutic efficacy.
This track will examine the evolving landscape of immunotherapy in oncology, highlighting recent breakthroughs and ongoing clinical trials. Participants will discuss the challenges and opportunities in harnessing the immune system to combat cancer.
This session will delve into the critical role of translational research in oncology, focusing on the conversion of laboratory discoveries into clinical applications. Case studies will illustrate successful translation of findings into therapeutic strategies.
This track will investigate the complex interactions between tumor cells and their microenvironment, including stromal cells, immune cells, and extracellular matrix components. Understanding these dynamics is essential for developing effective cancer therapies.
This session will highlight the significance of biomarkers in the early detection and prognosis of various cancers. Researchers will present their findings on novel biomarkers and their potential clinical applications.
This track will focus on the identification and validation of new therapeutic targets in oncology. Discussions will include the implications of targeting specific molecular pathways for cancer treatment.
This session will address the distinct challenges faced in the treatment of childhood cancers, including the need for tailored therapies. Innovative approaches and recent advancements in pediatric oncology will be discussed.
This track will explore the ethical considerations and disparities in access to cancer treatment across different populations. Participants will engage in discussions about equitable healthcare delivery and policy implications.
This session will focus on the methodologies and best practices for designing and conducting clinical trials in oncology. Emphasis will be placed on innovative trial designs and patient recruitment strategies.
This track will examine the integration of complementary therapies with conventional cancer treatments. Discussions will highlight the evidence supporting integrative approaches and their impact on patient outcomes.